News

The company has upgraded its existing operating system with centralized web-based application for its growing supply chain organization. Maestro is believed to have a flexible architecture which allows

INC424, an oral inhibitor of the JAK1 and JAK2 tyrosine kinases, is being evaluated in primary myelofibrosis as well as post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF),

MM-121 is a fully human monoclonal antibody that targets ErbB3. The study is intended to assess the safety and pharmacokinetics of MM-121 when administered in combination with cetuximab

CETP inhibition is believed to potentially raise HDL (good cholesterol) levels and help prevent cardiovascular disease. As per the deal, Simcere will receive exclusive rights to develop and

Ths system will be used as a centralized Customer Relationship Management (CRM) platform by UCB Nordics for Specialty, Market Access and Key Account Management (KAM) commercial teams throughout

EnWave has granted Merck an exclusive research license to use its technology and licensed patents for the duration of the evaluation, besides providing an option to obtain an

BioServe will help Fox Chase provide next generation sequencing capabilities as it has developed a new internal laboratory utilizing next-generation sequencing and analysis platforms and novel biological information

The move of the European agency is backed by two large, multi-national, Phase 3 clinical trials that demonstrated the efficacy of Dificlir as oral vancomycin to treat CDI.

microRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteins but instead regulate gene expression. Regulus’ expertise in microRNA therapeutics will